相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
Tobias Bexte et al.
ONCOIMMUNOLOGY (2022)
PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype
Arnika K. Wagner et al.
ISCIENCE (2022)
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma
Dickran Kazandjian et al.
ONCOLOGIST (2021)
Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis
Angelo Borsarelli Carvalho Brito et al.
THORACIC CANCER (2021)
Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation
Zachary Davis et al.
BLOOD ADVANCES (2021)
PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
Eileen McGowan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Daixi Ren et al.
MOLECULAR CANCER (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity
Haifeng Zhu et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Kellsye P. Fabian et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie et al.
EBIOMEDICINE (2020)
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2019)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani et al.
LANCET HAEMATOLOGY (2019)
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
Jianshu Wei et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells
Changjiang Guo et al.
MOLECULAR IMMUNOLOGY (2019)
Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma
Christiane Kuempers et al.
FRONTIERS IN MEDICINE (2019)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Estefania Paula Julia et al.
FRONTIERS IN IMMUNOLOGY (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
Fernando Concha-Benavente et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Y. Liu et al.
ONCOGENE (2017)
Natural killer cell-mediated immunosurveillance of human cancer
Karl-Johan Malmberg et al.
SEMINARS IN IMMUNOLOGY (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley et al.
CLINICAL CANCER RESEARCH (2017)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Katrin Toepfer et al.
JOURNAL OF IMMUNOLOGY (2015)
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Inger S. Nijhof et al.
CLINICAL CANCER RESEARCH (2015)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy
Tolga Sutlu et al.
HUMAN GENE THERAPY (2012)
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Cyril Fauriat et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
DAP10-and DAP12-associated receptors in innate immunity
Lewis L. Lanier
IMMUNOLOGICAL REVIEWS (2009)
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Evren Alici et al.
BLOOD (2008)
A multicolor panel of novel lentiviral gene ontology (LeGO) vectors for functional gene analysis
Kristoffer Weber et al.
MOLECULAR THERAPY (2008)
Up on the tightrope: natural killer cell activation and inhibition
Lewis L. Lanier
NATURE IMMUNOLOGY (2008)
Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
Evren Alici et al.
EXPERIMENTAL HEMATOLOGY (2007)
The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure
D Garrity et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Lentivirus-delivered stable gene silencing by RNAi in primary cells
SA Stewart et al.
RNA (2003)
DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells
J Wu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
